Resveratrol has been studied in a randomized, placebo-controlled, cross-over clinical trial. Organized jointly by French, Danish and Dutch, the study aimed to measure possible positive effects in several fatty acid oxidation disorders, some of which have muscle expression (carnitine palmitoyltransferase type II or CPTII deficiency):
- eight patients participated in the study, which took place over twenty weeks (8 weeks of treatment or placebo, 4 weeks of wash-out, and 8 weeks of cross-over),
- no change was noted in physical performance at the end of the test,
- the energy profile, in particular that of fatty acids, was not modified.
Accordingly, the authors do not recommend the prescription of this drug.
